Korean J Pain.  2023 Oct;36(4):405-407. 10.3344/kjp.23258.

Towards precision pain management—the case for targeting DRP1 in remifentanil-induced hyperalgesia

• Jung KT

• KMID: 2546703
• DOI: http://doi.org/10.3344/kjp.23258

Reference

1. Angst MS, Clark JD. 2006; Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology. 104:570–87. DOI: 10.1097/00000542-200603000-00025. PMID: 16508405.

2. Lee M, Silverman SM, Hansen H, Patel VB, Manchikanti L. 2011; A comprehensive review of opioid-induced hyperalgesia. Pain Physician. 14:145–61. DOI: 10.36076/ppj.2011/14/145. PMID: 21412369.

3. Cohen SP, Christo PJ, Wang S, Chen L, Stojanovic MP, Shields CH, et al. 2008; The effect of opioid dose and treatment duration on the perception of a painful standardized clinical stimulus. Reg Anesth Pain Med. 33:199–206. DOI: 10.1097/00115550-200805000-00002. PMID: 18433669.

4. Lee C, Kim YD, Kim JN. 2013; Antihyperalgesic effects of dexmedetomidine on high-dose remifentanil-induced hyperalgesia. Korean J Anesthesiol. 64:301–7. DOI: 10.4097/kjae.2013.64.4.301. PMID: 23646238. PMCID: PMC3640161. PMID: c4e19ca3f11b4b8ea94e933ac9d7d7e7.

5. Zhou S, Pan Y, Zhang Y, Gu L, Ma L, Xu Q, et al. 2023; Antisense oligodeoxynucleotides against dynamin-related protein 1 reduce remifentanil-induced hyperalgesia by modulating spinal N-methyl-D-aspartate receptor expression in rats. Korean J Pain. 36:316–27. DOI: 10.3344/kjp.22398. PMID: 37183652. PMCID: PMC10322665.

6. Gibellini L, Bianchini E, De Biasi S, Nasi M, Cossarizza A, Pinti M. 2015; Natural compounds modulating mitochondrial functions. Evid Based Complement Alternat Med. 2015:527209. DOI: 10.1155/2015/527209. PMID: 26167193. PMCID: PMC4489008.

7. Tsushima K, Bugger H, Wende AR, Soto J, Jenson GA, Tor AR, et al. 2018; Mitochondrial reactive oxygen species in lipotoxic hearts induce post-translational modifications of AKAP121, DRP1, and OPA1 that promote mitochondrial fission. Circ Res. 122:58–73. DOI: 10.1161/CIRCRESAHA.117.311307. PMID: 29092894. PMCID: PMC5756120.

8. Atkins K, Dasgupta A, Chen KH, Mewburn J, Archer SL. 2016; The role of Drp1 adaptor proteins MiD49 and MiD51 in mitochondrial fission: implications for human disease. Clin Sci (Lond). 130:1861–74. DOI: 10.1042/CS20160030. PMID: 27660309.

9. Petersen-Felix S, Curatolo M. 2002; Neuroplasticity--an important factor in acute and chronic pain. Swiss Med Wkly. 132:273–8. DOI: 10.4414/smw.2002.09913. PMID: 12362284. PMID: 55d1da494df34c33949dba5a79bd1955.

10. Woolf CJ, Salter MW. 2000; Neuronal plasticity: increasing the gain in pain. Science. 288:1765–9. DOI: 10.1126/science.288.5472.1765. PMID: 10846153.

11. Paoletti P, Bellone C, Zhou Q. 2013; NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat Rev Neurosci. 14:383–400. DOI: 10.1038/nrn3504. PMID: 23686171.

12. Mohan A, Fitzsimmons B, Zhao HT, Jiang Y, Mazur C, Swayze EE, et al. 2018; Antisense oligonucleotides selectively suppress target RNA in nociceptive neurons of the pain system and can ameliorate mechanical pain. Pain. 159:139–49. DOI: 10.1097/j.pain.0000000000001074. PMID: 28976422.

13. Roberts TC, Langer R, Wood MJA. 2020; Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 19:673–94. DOI: 10.1038/s41573-020-0075-7. PMID: 32782413. PMCID: PMC7419031.